Oncology drug gemcitabine injection approved by FDA

Business News Agency August 12th, the United States Food and Drug Administration (FDA) approved Hospira's oncology drug gemcitabine injection. The drug is a liquid formulation and the approved dosage specifications are: 200 mg, 1 gm, and 2 gm. The company expects to launch this new drug in September.

Hospira president Thomas Moore said that providing pharmacists with a solution form of gemcitabine will reduce their development cycle. Hospira's universal gemcitabine solution has enabled the medical community to obtain a low-cost, more convenient way to treat related tumors.